Dasiglucagon
FDA approved · RxGlucagon receptor agonist
Also known as: Zegalogue, ZP-GA-1, ZP4207, ZP-4207, dasiglucagonum, GLXC-23972, DA-72568
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 21 registered studies on ClinicalTrials.gov, most advanced Phase 3
- 2 cited sources. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Dasiglucagon, sold as Zegalogue, is a synthetic peptide analog of the hormone glucagon, modified to stay stable in a ready-to-use liquid form. It activates glucagon receptors in the liver, prompting the release of stored glucose into the blood and raising blood sugar levels.
What the evidence shows
It is FDA-approved for the treatment of severe hypoglycemia in people with diabetes aged 6 years and older, based on Phase 3 trials among about 21 registered human studies. Uses beyond this approved indication, such as other forms of low blood sugar, are still being studied and are not established.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.
Glucose-Driven Droplet Formation in Complexes of a Supramolecular Peptide and Therapeutic Protein.
Sources
- PubChem compound record (CID 126961379)
- FDA drug label on DailyMed
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.